In the first half of the year, another four products were approved by the FDA, and the overseas business revenue of this pharmaceutical company exceeded one billion yuan

Highlights on June 20, humanwell pharmaceutical released a notice that Yichang humanwell Pharmaceutical Co., Ltd., a holding subsidiary, received the FDA approval number for bupropion hydrochloride sustained-release tablets, which is the fourth foreign approved product since 2018 Humanwell pharmaceutical mentioned in its 2017 annual report that it strives to obtain more than 50 anda numbers during the 13th Five Year Plan period In recent years, the international business of humanwell pharmaceutical has entered a rapid development stage, and its overseas revenue is good news   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; font-size: 17px; letter-spacing: 0.544px; widows: 1; font-family: -apple-system-font, Bl inkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif; line-height: 25.6px; Color: rgb (62, 62, 62); border style: none none solid; text align: Center; border bottom width: 1px; border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> overseas business is growing rapidly, with revenues exceeding one billion in the past two years Figure 1: overseas business revenue of humanwell pharmaceutical in 2015-2017 (unit: 100 million yuan) (data source: annual report of listed companies) in recent years, humanwell pharmaceutical adheres to the implementation of internationalization strategy, accelerates the promotion of overseas drug R & D registration and business channel expansion In 2016, humanwell purchased epic pharma and its affiliated enterprises with us $550 million, achieving rapid development of international business scale Through the integration of domestic production capacity and the acquisition of epic Pharma, the company had nearly 20 anda numbers by the end of 2016, and about 400 drugs with product specifications were sold in the U.S market In 2016, the company achieved a sales revenue of 681 million yuan in the United States In 2017, the company jointly acquired Ansell for a total of US $600 million (60% of the company) Ltd global gender health business (including overseas gender health business and domestic jesborne company), and acquired ritedose with about 100 million US dollars Through the above acquisition, the company obtained overseas acquisition projects such as the priority right of technology introduction, enriched and expanded the product pipeline of the company's overseas business, and further enhanced the company's international advantages In 2017, the overseas business revenue of humanwell pharmaceutical increased to RMB 1.84 billion In the first quarter of 2018, the operating revenue of humanwell pharmaceutical was 4.438 billion yuan, an increase of 33.28% over the same period of the previous year The reason for the performance increase was that the company continued to promote the transformation and upgrading of the marketing system, actively expanded business channels at home and abroad, and steadily increased the revenue of the main medical and health businesses   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; font-size: 17px; letter-spacing: 0.544px; widows: 1; font-family: -apple-system-font, Bl inkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif; line-height: 25.6px; color: rgb(62, 62, 62); border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> with the rapid development of generics business in the United States, in the first half of 2018, four additional anda companies insisted on promoting the development of overseas business, especially the generics business in the United States According to the annual report data of humanwell, through the integration of domestic production capacity and the acquisition of epic Pharma, the company has nearly 20 anda numbers by the end of 2016 In 2017, the company and its subsidiaries received 3 American anda numbers of generic drugs In the first half of 2018, four products of humanwell have been approved by FDA Table 1: products approved by FDA in the first half of 2018 (data source: announcement of listed companies, statistics by announcement date) humanwell said that the company will continue to pass puke, Yichang humanwell and epic Pharma's overseas R & D team will accelerate the promotion of generic drug R & D projects, strive to obtain more than 50 anda numbers during the 13th Five Year Plan period, improve the company's market position in the U.S generic drug industry through the enrichment of product pipelines, and strive to enter the top 20 in the U.S generic drug industry within five years The U.S pharmaceutical market is the largest in the world, accounting for more than 30% of the global pharmaceutical market in the past 10 years According to some data, in 2015, the growth rate of American Medical Expenditure reached 8.5% Due to the increasing pressure of medical insurance and fee control, the market demand for generic drugs keeps increasing The total sales volume of generic drugs reaches 71.9 billion US dollars, and the compound annual growth rate is expected to reach 9.1% in the next five years Compared with the huge investment of patent drugs, the risk of generic drug development is relatively low After nearly 10 years of development, humanwell pharmaceutical has established drug production bases in Wuhan, Yichang and New York, which meet the cGMP standards of FDA The company has continued to strengthen drug R & D and channel expansion in the United States, and its overseas business performance has been growing rapidly In 2017, the sales revenue of preparations in the United States exceeded 1 billion yuan   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; font-size: 17px; letter-spacing: 0.544px; widows: 1; font-family: -apple-system-font, Bl inkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif; line-height: 25.6px; color: rgb(62, 62, 62); border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> with the development of Internet technology, e-commerce has developed rapidly from germination to rapid development, and the gender health industry has ushered in a golden era of development According to the data, from 2015 to 2020, the global market size of adult products (excluding condoms) will increase from US $12.37 billion to US $16.31 billion, with a compound annual growth rate of 5.68% During the same period, the global market size of condoms will increase from US $4.36 billion to us $7.03 billion, with a compound annual growth rate of 10.03% Over the years, humanwell pharmaceutical has actively deployed the pharmaceutical and health industry, and its subsidiaries have cultivated brands and product lines with certain popularity, such as "aware love health", "key", "Sydney" In May 2017, humanwell pharmaceutical announced that it and CITIC Capital Cupid Investment Limited jointly acquired the global gender health business of Ansell Ltd., the second largest enterprise in the global condom market (including overseas gender health business and domestic Jasper company), with a total of US $600 million (60% of the company) Wang Xuehai, chairman of humanwell pharmaceutical, once said, "the e-commerce of Jasper in 2016 has tripled compared with 2015, and the offline growth is slightly slower than the online growth It can be seen that, driven by e-commerce, the industry has been effectively improved, and our current goal is to increase sales to one billion US dollars in the world in five years " The company acquired Ansell Ltd gender health business, established a holding subsidiary leforth health group (the company holds 76.33% equity) in Singapore in 2017 The company operates lifestyles, Jissbon, MANIX, unimil, blowtex, skyn and other well-known condom brands in nearly 60 countries, including China, the United States, Japan, Australia, Brazil, Thailand, and has R & D centers and latex production centers Base cooperation, focus on research and development of gender health products The company was included in the consolidated statement of humanwell pharmaceutical in September 2017 From September to December 2017, the company realized an operating revenue of 522.3598 million yuan and a revenue of 35.9567 million yuan from gender health business Wang Xuehai, chairman of humanwell pharmaceutical, said that the company's global gender health business would take the opportunity to list in Hong Kong, develop independently, and form a stable management structure and internal growth momentum Recently, Li qianlun, Secretary of the board of directors of humanwell pharmaceutical, said at the 2018 online group reception day for investors of Listed Companies in Hubei province that, according to relevant regulations, the global gender health business of lefos group could not apply for listing until 2020 at the earliest Source: annual report, announcement, China business report, etc